Advisory Services Transforming biopharma - IQVIA
Transcript of Advisory Services Transforming biopharma - IQVIA
Transforming biopharmato accelerate the development and commercialization of innovative therapies for patients worldwide
Advisory Services
Strategic problem-solving and evidence generationIndustry-leading perspectives
Our team of seasoned management consultants draw upon their extensive advisory services experience and focus on accelerating superior outcomes guided by connected insights, strategic thinking and actionable solutions.
Domain expertise with scale and reachGlobal footprint and scale
Quintiles Advisory Services brings deep expertise across multiple domains and harnesses the power of hybrid teams including our 1,100 medical doctors and more than 1,050 PhDs across our global organization, with over 30 years of clinical research and commercial experience and ability to serve approximately 100 countries to help bring actionable insights and solutions.
Rich data integrationInnovative technology
Through the strength of our extensive data and analytical engines, we provide evidence to support asset development, guide the creation of effective implementation plans, and deliver high quality, integrated global solutions.
Strategy to operationsAdvise to operate
We offer strategic advice which can lead to fulfilling operational partnerships with Quintiles, from outsourcing of clinical development and mature products to joint operations of functions throughout the value chain.
What makes us differentQuintiles Advisory Services is built on focus, knowledge and an understanding of healthcare.
Who we are
Quintiles Advisory Services, the consulting arm of Quintiles, is a different kind of healthcare advisory group – built on a blend of deep industry and therapeutic expertise, strategic problem-solving skills and rich data assets.
We bring a broad understanding of end-to-end drug development and healthcare delivery to help firms develop the strategies and capabilities needed to develop and launch products with the greatest potential for commercial success and patient outcomes, based on the right evidence needed to demonstrate value.
We operate on the principle that the best evidence is based on connected, broad insight which results in actionable solutions, faster implementation and ultimately superior outcomes/value.
Quintiles Advisory Services core solutionsOur ability to leverage the broader operational capabilities across the global Quintiles organization, allows us to also bring perspectives and solutions developed through real-world experience across the value chain.
Market Intelligence & Market Planning
Use advanced primary research methodologies and decision modeling to generate unique market insights and build plans for clinical and commercial development throughout the product life cycle.
Technical & Commercial Due Diligence Help biopharma clients decide whether to
develop or acquire assets tailored to the portfolio, therapeutic area/disease or asset level using real-world data and technical probability analysis.
Integrated Asset Development Planning
Deliver key asset planning components required for successful asset development and commercialization including the target product profile, clinical development plan, market access plan, launch plan and commercialization.
Clinical Development TransformationLeverage novel approaches for clinical
trial design and execution that improve the probability of commercial success and maximize return on investment for products in development.
Regulatory & Safety OptimizationHelp companies assess and optimize
the value, approach and key activities required to manage their regulatory, safety and benefit risk management (BRM) capabilities, including virtualization.
Enterprise Quality Management & Compliance
Support clients in all aspects of proactive and reactive global quality and regulatory compliance, including developing regulatory strategies, conducting compliance audits & gap analyses, vendor audits and preparing responses to FDA 483 citations and warning letters.
Value & Outcomes StrategyHelp biopharma companies design,
develop and execute evidence plans that clearly articulate and support the value story for a product or device with rigorous, compelling data targeted to key healthcare system stakeholders, including health economics and outcomes research, patient-centered endpoints, market access and policy analysis.
Innovative Launch StrategyProvide asset and market-tailored
launch strategy and support which take into account local market variability, evidence expectations, higher standards for market access, new channels and stakeholders.
Mature Product ManagementHelp pharmaceutical companies
consider alternatives for creating value from their mature products, including sales and marketing promotion and divestment. Quintiles also offers outsourcing capabilities to develop and implement programs aimed at capturing incremental value.
End-to-end PartnershipsDesign and execute custom strategic
partnership models for biopharma companies, including providing bench strength or outsourcing capabilities across the product life cycle, from strategy and early phase to post-authorization and commercial.
Other focus areas
• Biosimilars
• Personalized Medicine and Diagnostics
• Orphan Drugs
• Predictive Analytics
Our peopleElgar Peerschke President, Advisory Services
Elgar brings more than 25 years of experience in providing advisory solutions to life sciences clients
across the global healthcare industry.
Prior to joining Quintiles, Elgar served as a senior executive in its Global Healthcare Practice Group at Bain & Company and spent more than a decade at McKinsey and Company in various leadership roles.
John Doyle, DrPH, MPH Senior Vice President, Advisory Services
John leads the Value & Outcomes efforts at Quintiles and maintains an
adjunct faculty position at the Mailman School of Public Health at Columbia University.
Prior to joining Quintiles, John served as the President and Chief Operating Officer of Analytica International, Inc., and led a health economics research group at Bristol-Myers Squibb Company.
Avi Kulkarni, PhD Senior Vice President, Advisory Services
Avi brings more than 25 years of life science experience, and a proven
track record of thought leadership in optimizing the research development process to improve the delivery of tailored therapeutics.
Prior to joining Quintiles, Avi was a partner at Strategy& (formerly Booz & Company and Booz Allen & Hamilton) and led the R&D and Medical Transformation business.
Adrian McKemey, PhD Senior Vice President, Advisory Services
Adrian focuses on business transformation, portfolio management,
risk partnering, scenario planning and outsourcing strategies.
Prior to joining Quintiles, Adrian worked in the Health Care practice at BCG and was a particle physicist and a tenured faculty member at Brunel University in London.
Mark Mozeson Senior Vice President, Advisory Services
With nearly 30 years of life science experience, Mark ensures the most
senior-level oversight and management for strategic accounts and customer relationships for Quintiles Advisory Services.
Prior to joining Quintiles, Mark was a partner at Oliver Wyman and led the Health & Life Science practice.
Frederic “Rick” Sax, MD Senior Vice President, Advisory Services
Rick’s career spans nearly 20 years in the biopharmaceutical industry,
leveraging drug development design expertise to help partners make knowledge-based decisions
Prior to joining Quintiles, Rick served as the Vice President, Clinical Design Strategies of AstraZeneca’s clinical development leadership team
Dean Summerfield, DPhil Senior Vice President, Advisory Services
Dean has nearly 20 years of experience in providing advisory
solutions to life sciences clients.
He leads advisory services for Integrated Healthcare Services (IHS) at Quintiles and is Managing Director for the European Advisory Services group.
Marc Hennebert Senior Vice President, Advisory Services
Marc has nearly 30 years of experience with emphasis on
building and leading teams for complex consulting engagements.
Prior to joining Quintiles, Marc set-up new practices for IMS Health, served as managing partner of the Life Science & Chemicals practice for Strategic Decision Group and as a partner at Arthur D. Little.
Case study
Client situation: A leading biopharmaceutical company wanted to evolve their clinical research and operations to increase speed and agility of development and improve the probability of success for their pipeline while effectively managing R&D spend.
Results: The company transformed its R&D into a lean virtual operation, enhancing its strategic capabilities while leveraging external excellence in clinical operations. The partnership model enabled the company to increase study volume by 50%, achieve a 40% internal reduction in clinical development FTEs per study and also avoid costly investments in redundant capabilities and IT systems. In addition, Quintiles’ scientific expertise in new therapeutic areas, market access knowledge and proficiency was important in helping the client expand their portfolio and optimize clinical development.
Our actions: Quintiles responded by bringing our subject matter expertise in clinical development, process excellence and change management to partner with the client. Together we created and fully implemented a flexible end-to-end operating model, encompassing strategy and operations from early clinical phase to launch and life cycle management.
• Approximately 200 process maps jointly developed
• Detailed RACI created to streamline distribution of work
• Organizational design and modeling for client
• Partnership manual linked with training
• Aligned metrics at study, program and executive levels
• Technology mapping and strategy
• 100+ people from both organizations contributed as team members and became change champions
Partnership Governance Structure
Partnership Executive Committee
Executive Co-chairs
Partnership Directors Finance Clinical
Science LeadStrategic Drug Dev.
Partnership Operating Committee Quality Council
Partnership Mgmt.
DeliveryLeads Finance Information
TechnologyProcessLeads
Clinical Quality Leads
Partnership Management Office Innovation and Technology Committee Resourcing Committee
ProcessLeads Metrics Leads Innovation
LeadsTechnology
Leads HR Leads
Joint Team
Partner
Sponsor
Program 1 Program 2 Program 3
Program Directors Program Directors Program Directors
Study 1 Study 2
PMs PMs
Study 1 Study 2
PMs PMs
Study 1 Study 2 Study 3
PMs PMs PMs
Work Plan for Initial Project Phase
Week 1-6 Week 7-13 Week 14-16
Operating Model Detailed Design Roadmap Implementation
Operating Model Design End-to End Process Design
Organizational Plan
Governance Design
Productivity Assessment Performance/Contracting Design
Technology Assessment Technology Plan
Transition Risk Assessment Transition Design
Resource Management/Talent Retention
Communications
Project and Change Management
Operating Model Workshop
Interim Readout(top line estimates)
Interim Readout(detailed design)
Final Readout
Implementation Roadmap and Plan
High-Level Operating Model Transformation
FunctionCurrent State
Future StateTA #1 TA #2 TA #3
Clinical Research Sponsor Sponsor Mixed Mixed
Medical Writing Sponsor Sponsor Mixed Mixed
Project Mgmt Mixed Mixed Partner Partner
Data Mgmt Mixed Sponsor Sponsor Partner
Biostatistics Sponsor Sponsor Partner Partner
Vendor Mgmt Sponsor Mixed Mixed Partner
Site Monitoring Partner Partner Partner Partner
Clinical Supplies Sponsor Mixed Mixed Mixed
Quality Assurance Sponsor Sponsor Sponsor Mixed
Contact usToll free: 1 866 267 4479 Direct: +1 973 850 7571Website: www.quintiles.com/advisoryservices Email: [email protected] C
opyr
ight
© 2
016
Qui
ntile
s. A
ll rig
hts
rese
rved
. 01
.005
7-3-
03.1
6